论文部分内容阅读
目的:考察(对)固定剂量复合剂(FDC)(与板式组合药)对(治疗)初治涂阳肺结核的治疗效果(进行对比和评价)。方法:通过在中文期刊数据库检索1994-2012年间发表的关于固定剂量复合剂与板式组合药治疗初治涂阳肺结核效果对比的文献,按照预设标准筛选文献,采用stata11.0统计软件进行meta分析。结果:共有18篇文献纳入meta分析,结果显示:基于FDC的化疗方案与板式组合药化疗方案相比,FDC组的治愈率高于板式组合药对照组,差异有统计学意义(固定效应模型OR=2.03,95%CI=1.63-2.53);对2月末痰菌阴转率(固定效应OR=1.09,95%CI=0.92-1.31)、3月末痰菌阴转率(固定效应OR=1.21,95%CI=0.89-1.65)和严重药物不良反应率(随机效应OR=0.31,95%CI=0.06-1.49)等指标的影响则没有统计学差异。结论:现有文献结果支持FDC治疗初治涂阳肺结核患者效果比板式组合药更好。
OBJECTIVE: To investigate the effect of (versus) fixed-dose combination (FDC) versus plate therapy on the treatment of initial smear-positive pulmonary tuberculosis (for comparison and evaluation). Methods: The literature about the comparison of the effect of fixed-dose combination with plate-type combination therapy on smear-positive pulmonary tuberculosis was searched in the Chinese Journal Database from 1994 to 2012. The literatures were screened according to the pre-set standards and analyzed by stata11.0 statistical software . Results: A total of 18 articles were included in the meta-analysis. The results showed that the FDC-based chemotherapy was superior to the plate-based combination chemotherapy in the treatment of FDC and the difference was statistically significant (fixed effect model OR = 2.03, 95% CI = 1.63-2.53). The rate of sputum negative conversion (fixed effect OR = 1.09, 95% CI = 0.92-1.31) 95% CI = 0.89-1.65) and adverse drug reaction rate (random effect OR = 0.31, 95% CI = 0.06-1.49) had no significant difference. Conclusion: The results of the current literature support FDC treatment of smear-positive pulmonary tuberculosis patients better than the plate-type combination.